Screening of the H69 and V70 deletions in the SARS-CoV-2 spike protein with a RT-PCR diagnosis assay reveals low prevalence in Lyon, France

Antonin Bal*[1,2], Gregory Destras*[1,2], Alexandre Gaymard*[1,2], Hadrien Regue[1], Quentin Semanas[1], Constance d'Aubarde[3], Geneviève Billaud[1,2], Frédéric Laurent[4,5], Claudia Gonzales[1], Martine Valette[1], Bruno Lina[1,2], Florence Morfin[1,2], Laurence Josset [1,2] and the COVID-Diagnosis HCL Study Group

[1]Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

[2] CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.

[3] Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France

[4] CIRI - Centre International de Recherche en Infectiologie, Team Pathogenesis of staphylococcal infections Inserm U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France.

[5]Laboratoire de Bactériologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Corresponding author: Laurence Josset, Pharm.D, Ph.D

Associate Professor
Lyon 1 University
Hospices Civils de Lyon, France
National reference center for respiratory viruses
Phone: +33 (0)4 72 12 96 47
Email: laurence.josset@chu-lyon.fr

*equal contribution

Abstract

The H69 and V70 deletions in SARS-CoV-2 spike protein have been detected in mink and

human infections. We found that these deletions resulted in a false negative result for the spike

target of a commercial RT-PCR assay. From August 3rd to November 1st, 39/6964 (0.56%) of

positive tests performed in Lyon, France, displayed a S negative profile suggesting a limited

circulation of the deleted variant. This RT-PCR assay could be useful to address the risk of the

mink variant's spreading.

A SARS-CoV-2 variant detected both in minks and humans in Denmark has raised concerns about mutations associated with potential reduced susceptibility to neutralizing antibodies [1, 2]. This variant harbors a set of mutations identified in the spike (S) glycoprotein including Y453F, I692V, M1229I as well as two amino acid deletions H69del/V70del. To address the risk of spreading, an easy-to use method enabling a fast large-scale screening is urgently needed.

H69del and V70del identification during routine genomic surveillance

As part of routine SARS-CoV-2 genomic surveillance performed at national reference centre for respiratory viruses (Lyon, France), a 6-nucleotide deletion (21765-21770) within the S gene was identified in two nasopharyngeal samples. The SARS-CoV-2 whole genomes corresponding to these samples were sequenced using the ARTIC amplicon based protocol combined with Illumina sequencing (Illumina, San Diego, USA) on NextSeq500 platform (GISAID accession numbers : EPI_ISL_582112, EPI_ISL_582120). Using CoV-GLUE resource [3], we found that the S deletion 21765-21770 led to the removal of 2 amino acid (H69del and V70del) in the N-terminal domain of the S protein (Figure 1A). Importantly Y453F, I692V and M1229I mutations were not detected.

These samples were collected from two SARS-CoV-2 infected health-care workers (HCW) working in the same geriatric unit on September 1st and 7th, respectively. They were 58 and 59 years and developed mild COVID-19. No serological testing nor RT-PCR testing were performed before this episode. For the HCW sampled on September 1st, serological testing performed on November 4th was positive using the Architect SARS-CoV-2 IgG assay (Abbott, North Chicago, USA). The SARS-CoV-2 detection had been performed with the Applied Biosystems TaqPath COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) which includes the ORF1ab, S and N gene targets. For these two samples, the S target was negative while ORF1ab and N targets were positive with Ct values < 25 (Figure 1B).

H69del and V70del screening with RT-PCR kit

In order to assess the use of TaqPath RT-PCR kit for the screening of the H69del and V70del, 15 additional nasopharyngeal SARS-CoV-2 positive samples were sequenced. Among them, 4 were negative for the S target while 11 presented an amplification of the S target. The sequencing results were fully concordant with the RT-PCR profiles (100% of the S negative profile had the H69 and V70 deletions while 100% of the S positive profile did not have these deletions). We then performed a retrospective analysis of RT-PCR results performed in our lab with the TaqPath kit from August 3rd to November 1st among HCW and general population. To avoid misinterpretation, we selected only positive samples with a Ct value < 25 for the N target, the most sensitive target of the test. By doing so, we found that 39/6964 (0.56%) of positive tests performed with the TaqPath kit had no amplification of the S gene. No significant increase of the S negative profile was noticed over time with a proportion ranging from 0% (week # 32, 33, 34, and 42) to 2.91% (week # 35) (Figure 1C).

Discussion and conclusion

In the present study, we explore the ability of a commercial RT-PCR assay for screening the H69 and V70 deletions in S, previously associated with mink and human infections [2]. The prevalence of the S negative profile was relatively low and steady in Lyon, France, from August to November 2020. However, this result should be interpreted with caution. As a limited number of samples with the S negative profile in RT-PCR were sequenced, we could not exclude the presence of other S mutations associated with this profile. Therefore the prevalence of these S variant could be lower than 0.56 %. Moreover we could not determine whether the deletion affected the primer or the probe binding region as their coordinates were not available.

Of note, the present diagnostics kit did not lead to a false negative conclusion as the two other targets remain positive. Few manufacturers have included a S target which is characterized by

a high genetic diversity [4, 5]. Importantly, the receptor binding domain (RBD) in the S protein

is the main target of SARS-CoV-2 neutralizing antibodies [6].

According to CoV-GLUE resource [3] (last update from GISAID: November 2nd), the S

deletion 21765-21770 has been identified in 855 other sequences worldwide (>95% in Europe)

corresponding to a detection rate of about 0.5% (187, 770 SARS-CoV-2 sequences have been

deposited on GISAID as of November 2nd). Interestingly, only 10 sequences including 7

European sequences were sampled before September 1st. Among these European sequences,

5/7 were sampled in March including a French sequence sampled in Marseille on March 23th

France [7].

It should be underlined that, except the mutation Y453F within the RBD, the other mutations

detected in mink and humans in Denmark have not been associated with significant changes

both in SARS-CoV-2 pathogenesis and host-immune response [8, 9]. Nonetheless, H69del and

V70del are in N-terminal domain which might play a role in COVID-19 pathogenesis, by

interacting with new identified lung receptors [10] or by being a target of neutralizing antibodies

[11]. The S variants need to be early identified and characterised as recently done for the

circulating S variant N439K which shows evidence of immune evasion [12, 13].

In conclusion our study emphasizes (i) the crucial role of routine genomic surveillance for

identifying S variants (ii) that RT-PCR assay could be a gateway for S deletions screening and

a high throughput tool to monitor their spread in the global population. For the SARS-CoV-2

positive samples but negative for the S target, whole genome sequencing should be performed

in order to characterize all the mutations of the S protein. Further studies are needed to assess

the impact of H69del and V70del on the host-immune response and vaccine efficiency.

Figure 1

A. Visualisation of the spike deletion 21765-21770 (in green) compared with the reference sequence Wuhan-Hu-1 (in blue) using genome visualization tool from the CoV-GLUE online resource. The 21765-21770 deletion results in H69 and V70 deletions, with ATC (21764-21771-21772) coding for an isoleucine amino acid (I) B. Amplification curves obtained with TaqPath COVID-19 RT-PCR Kit for samples with the S deletion 21765-21770. The three targets included in the RT-PCR kit are represented by a different colour. The amplification curve of the internal control is also represented (MS2, red curve) C. Prevalence of the S negative profile with TaqPath COVID-19 RT-PCR Kit from August 3rd (week 32) to November 1st (week 44).

Data availability

SARS-CoV-2 genomes sequenced in this study were deposited in the GISAID database (EPI_ISL_582110, EPI_ISL_582111, EPI_ISL_582112, EPI_ISL_582113, EPI_ISL_582114, EPI_ISL_582115, EPI_ISL_582116, EPI_ISL_582117, EPI_ISL_582118, EPI_ISL_582119, EPI_ISL_582120, EPI_ISL_582508, EPI_ISL_623098, EPI_ISL_623099, EPI_ISL_623100, EPI_ISL_623101, EPI_ISL_623102)

Ethics statement

Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78–17 on 06/01/1978 and Décret 2019–536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N°41).

Acknowledgements

We would like to thank all microbiologist, clinicians, laboratory technicians who contributed to this investigation. We thank the authors, the originating and submitting laboratories for their sequence and metadata shared through GISAID on which this research is based. We gratefully acknowledge all the members of CoV-GLUE, Nextstrain.org, and virological.org for sharing their analysis in real-time.

COVID-Diagnosis HCL Study Group

Maude Bouscambert, Jean-Sébastien Casalegno, Emilie Frobert, Vanessa Escuret, Vinca Icard,

Marion Jeannoel, Marie-Paule Milon, Yahia Mekki, Christophe Ramière, Caroline Scholtès,

Jean-Claude Tardy, Mary-Anne Trabaud, Isabelle Schuffenecker

References

1. ECDC to assess risk associated with spread of SARS-CoV-2 in mink farms. European
Centre for Disease Prevention and Control. 2020. https://www.ecdc.europa.eu/en/news-
events/ecdc-assess-risk-associated-spread-sars-cov-2-mink-farms. Accessed 8 Nov 2020.

2. Statens Serum Institut. Mutationer i minkvirus.
https://www.ssi.dk/aktuelt/nyheder/2020/mutationer-i-minkvirus. Accessed 8 Nov 2020.

3. Singer J, Gifford R, Cotten M, Robertson D. CoV-GLUE: A Web Application for Tracking
SARS-CoV-2 Genomic Variation. 2020. doi:10.20944/preprints202006.0225.v1.

4. Sheikh JA, Singh J, Singh H, Jamal S, Khubaib M, Kohli S, et al. Emerging genetic
diversity among clinical isolates of SARS-CoV-2: Lessons for today. Infect Genet Evol.
2020;84:104330.

5. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Emergence of
genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol.
2020;83:104351.

6. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by
SARS-CoV-2 infection. Nature. 2020;584:115–9.

7. Levasseur A, Delerce J, Caputo A, Brechard L, Colson P, Lagier J-C, et al. Genomic
diversity and evolution of coronavirus (SARS-CoV-2) in France from 309 COVID-19-
infected patients. bioRxiv. 2020;:2020.09.04.282616.

8. GISAID - Mutations in spike putatively linked to outbreak in Danish mink farms.
https://www.gisaid.org/references/gisaid-in-the-news/mutations-in-spike-putatively-linked-to-
outbreak-in-danish-mink-farms/. Accessed 8 Nov 2020.

9. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to
SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
Science. 2020;369:1014–8.

10. Soh WT, Liu Y, Nakayama EE, Ono C, Torii S, Nakagami H, et al. The N-terminal
domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN
and DC-SIGN. bioRxiv. 2020;:2020.11.05.369264.

11. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody
binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650–
5.

12. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, Filipe A da S, Wojcechowskyj JA, et
al. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading
antibody-mediated immunity. bioRxiv. 2020;:2020.11.04.355842.

13. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from
neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9.